Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-27
EVO [neutral]
Evotec SE
-63.22%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Market Cap
EUR 612.5M
Pitch Price
EUR 9.13
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.42
P/E
-3.10
EV/Sales
0.87
Sector
Life Sciences Tools and Services
Category
value
Evotech: Biotech Growth Play at a Discounted Sales Multiple
EVO: Drug discovery platform. Recent €11/share buyout rumors by HALO, management blocked. Now €9.24, lowest since 2017 despite 3x revenue. NVO invested at $21/share. Biotech downcycle due to rates, but <3x sales multiple seems low given growth and margins. Management sees higher fair value.
Read full article (1 min)